Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin

被引：2
|
作者：
Moore, Gillian C.
Redfern, Jan
Shiach, Caroline R.
Webb, Kevin
Jones, Andrew M.
机构：
[1] Wythenshawe Hosp, NW Lung Ctr, Manchester Adult Cyst Fibrosis Unit, Manchester M23 9LT, Lancs, England
[2] Wythenshawe Hosp, Dept Haematol, Manchester M23 9LT, Lancs, England
来源：
JOURNAL OF CYSTIC FIBROSIS | 2007年 / 6卷 / 03期
关键词：
cystic fibrosis; ciprofloxacin; coagulopathy; INR; APTT;
D O I：
10.1016/j.jcf.2006.08.002
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
We report two cases of prolonged blood clotting times as demonstrated by a raised international normalised ratio and elevated activated partial thromboplastin time in patients with cystic fibrosis taking ciprofloxacin. The potential mechanisms of a coagulopathy of this picture as an adverse drug reaction with ciprofloxacin are discussed along with the possible clinical consequences for patients with cystic fibrosis. (C) 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：209 / 211
页数：3
相关论文
共 50 条
  • [31] Cystic fibrosis mutations and associated haplotypes in Turkish cystic fibrosis patients
    Onay, T
    Zielenski, J
    Topaloglu, O
    Gokgoz, N
    Kayserili, H
    Apak, MY
    Camcioglu, Y
    Cokugras, H
    Akcakaya, N
    Tsui, LC
    Kirdar, B
    HUMAN BIOLOGY, 2001, 73 (02) : 191 - 203
  • [32] Cystic fibrosis transmembrane regulator haplotypes in households of patients with cystic fibrosis
    Furgeri, Daniela Tenorio
    Lima Marson, Fernando Augusto
    Araujo Correia, Cyntia Arivabeni
    Ribeiro, Jose Dirceu
    Bertuzzo, Carmen Silvia
    GENE, 2018, 641 : 137 - 143
  • [33] When is cystic fibrosis not cystic fibrosis? The importance of appropriately classifying patients
    Faro, Albert
    Goss, Christopher
    Cromwell, Elizabeth
    Elbert, Alex
    Brown, Anne W.
    Marshall, Bruce C.
    RESPIRATORY MEDICINE, 2022, 193
  • [34] Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis
    Maiz Carro, Luis
    Lamas Ferreiro, Adelaida
    de Valbuena Maiz, Marta Ruiz
    Wagner Struwing, Carolin
    Gabilondo Alvarez, Gustavo
    Suarez Cortina, Lucrecia
    MEDICINA CLINICA, 2012, 138 (02): : 57 - 59
  • [35] First report of cystic fibrosis mutations in Libyan cystic fibrosis patients
    Fredj, Sondess Hadj
    Fattoum, Slaheddine
    Chabchoub, Abdelraouf
    Messaoud, Taieb
    ANNALS OF HUMAN BIOLOGY, 2011, 38 (05) : 561 - 563
  • [36] Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients?
    Costa Brzezinski, Lorena Xavier
    Riedi, Carlos Antonio
    Kussek, Paulo
    de Melo de Souza, Helena Homem
    Rosario, Nelson
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2011, 37 (03) : 341 - 347
  • [37] Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity Against Pseudomonas aeruginosa
    Cho, Do-Yeon
    Lim, Dong Jin
    Mackey, Calvin
    Skinner, Daniel
    Zhang, Shaoyan
    McCormick, Justin
    Woodworth, Bradford A.
    AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2019, 33 (02) : 129 - 136
  • [38] Ivacaftor for patients with cystic fibrosis
    Wainwright, Claire E.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2014, 8 (05) : 533 - 538
  • [39] Diets for patients with cystic fibrosis
    Wächtershäuser, A
    Bargon, JG
    Stein, J
    ERNAHRUNGS-UMSCHAU, 2002, 49 (10): : 380 - +
  • [40] Aspergillosis in cystic fibrosis patients
    Guillot, M
    El Hachem, C
    Amiour, M
    Delaisi, B
    Reinert, P
    ARCHIVES DE PEDIATRIE, 2003, 10 : 588S - 591S
12345